DYAX

Dyax's BLA for angioedema drug wins FDA priority review - 11/24 - 07:10 AM ET

UPDATE 1-Dyax's genetic disease drug granted fast review - 11/21 - 01:13 PM ET

BRIEF-Dyax says FDA grants priority review for hereditary angioedema therapy - 11/21 - 11:35 AM ET

FDA Accepts Filing and Grants Priority Review for DX-88 for Hereditary Angioedema - 11/21 - 11:30 AM ET

DYAX: To Present At Lazard Capital Healthcare Conference @ 16:40 ET [delayed] - 11/18 - 03:24 PM ET

DYAX: To Present At Credit Suisse Healthcare Conference @ 16:00 ET [delayed] - 11/13 - 02:23 PM ET

DYAX: To Present At Rodman & Renshaw Investment Conference @ 09:30 ET [delayed] - 11/12 - 07:54 AM ET

First-Ever Study Conducted Demonstrating Economic, Individual, and Societal Burden of Hereditary Angioedema - 11/10 - 07:30 AM ET

Dyax Corp. to Present at the Rodman & Renshaw Healthcare Conference - 11/05 - 07:30 AM ET

Dyax Corp posts figures for third quarter 2008 - 10/23 - 08:25 AM ET

BRIEF-Dyax Q3 results - 10/22 - 07:44 AM ET

DYAX CORP REUTERS ESTIMATES Q3 SHR VIEW $-0.21, REV VIEW $8.81 MLN - 10/22 - 07:36 AM ET

DYAX CORP Q3 SHR LOSS $0.43 INCLUDING ITEMS - 10/22 - 07:32 AM ET

DYAX CORP Q3 REVENUE $5.5 MLN VS $2.6 MLN - 10/22 - 07:32 AM ET

Dyax Corp. Announces Third Quarter 2008 Financial Results - 10/22 - 07:30 AM ET

DYAX: Gustav A. Christensen to Become CEO; Henry E. Blair Remains Chairman - 10/20 - 08:44 AM ET

BRIEF-Dyax announces CEO transition plan - 10/20 - 07:34 AM ET

DYAX CORP SAYS GUSTAV CHRISTENSEN TO SUCCEED HENRY BLAIR AS PRES AND CEO JAN 1 - 10/20 - 07:32 AM ET

Dyax Announces CEO Transition Plan - 10/20 - 07:30 AM ET

Dyax Corp. to Host Third Quarter 2008 Earnings Call and Webcast - 10/15 - 07:30 AM ET

Page 1 of 6     1  2   3   4   5   >   >>|     Previous  |  Next

<< Back to Stock Index